Project on

A review on the effect and treatment of respiratory disease caused by syncytial virus

[In the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy]

Submitted To

The Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

Submitted By

Jerin Tamanna

Student ID: 191-29-1563

Batch: 21th (D)

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

……

May 2023

APPROVAL

This project paper, **"A review on the effect and treatment of respiratory disease caused by syncytial virus"**, submitted to the Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to its style and contents.

BOARD OF EXAMINERS

……

Dr. Muniruddin Ahmed

Professor and Head,

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

…… Internal Examiner 1

…… . Internal Examiner 2

…… External Examiner 3

DECLARATION

I hereby declare that this project report, **"A review on the effect and treatment of respiratory disease caused by syncytial virus"**, is done by me under the supervision Most. Sumaiya Khatun Khli Lecturer, I am declaring that this Project is my original work. I also declare that neither this project nor any part thereof has been submitted elsewhere for the award of Bachelor or any degree.

Supervised by



……

Most. Sumaiya Khatun Kali

Lecturer

Department of Pharmacy

Daffodil International University.

Submitted By

……

Jerin Tamanna

ID: 191-29-1563

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

ACKNOWLEDGEMENT

I might want to communicate my profound applause to the All-powerful Allah who has given me the capacity to finish my undertaking work and the chance to concentrate in this subject.

I'm a lot of thankful to my honorable project supervisor Most. Sumaiya Khatun Khli Lecturer, Department of Pharmacy, Daffodil International University.

I would like to express my humble regards to Dr. Muniruddin Ahmed, Professor and Head, Department of Pharmacy, Daffodil International University.

I also wish to offer my respect to all of the teachers of Pharmacy Department, Daffodil International University and thankful to other members for their excellent cooperation with us.

Finally, I would like to express my gratitude towards my parents and other family members for their kind cooperation and encouragement which helped me in completion of this project.

My Parents

The persons who always encourage me in every sphere of my life

Abstract

The treatment and management of respiratory syncytial virus (RSV) infections in children are discussed in this review of the state of the science. Regrettably, there is no effective treatment at this time. Purpose of this review to know better diagnosis & treatments procedure of Respiratory syncytial virus. Methods for assembly and analyzing data, collected number of many related review paper from 2000 to 2022 review paper by using many search engines like PubMed, Research Gate, Google scholar and Medline etc. Corticosteroids and bronchodilators have not yet been proven to be effective. Ribavirin use is restricted to a very small number of high risk T-cell immunodeficient patients who have been thoroughly documented. Investigations on the effectiveness of vitamin A, interferon, and antibiotics produced underwhelming findings. Potential vaccines have been developed through vaccination research, including the recombinant vaccine BBG2Na, a subunit vaccine PFP-2, and vaccinations that are temperature- and cold-sensitive. The effects of bronchodilators (albuterol, metaproterenol, or ipratropium) were examined in a total of 24 published investigations. RSV infection manifestations have also been treated with epinephrine, which can be administered orally or intravenously (racemic epinephrine). Clinical practice recommendations are undeniably very efficient, and once implemented, they can be maintained and the gains made can continue. There are at least three different research lab methods for RSV identification. Immunofluorescence and enzyme immunoassay are two methods used to check for RSV antigens in nasal washes.

Contents

List of figures

Chapter 1

Introduction

1.1 Introduction

In newborns and young children around the world, respiratory syncytial virus (RSV) is the most common responsible for serious respiratory tract infections. A significant public health issues Every year, this issue kills numerous million children under the age of five around the world and costs the healthcare system hundreds of millions of dollars to treat affected kids. [1] RSV lower respiratory tract infectious diseases are thought to cause 100,000 to 125,000 hospitalizations and up to 450 fatalities annually in the United States. Prematurely born children and people with chronic lung diseases may experience very severe effects (CLD). In moreover, research suggests that early infection increases the risk of change significantly airways and the emergence of asthma in children. the financial strain on the healthcare system. [2] Ultimately, it is now understood to be a significant source of morbidity and mortality in immunocompromised children, adults, and fragile elderly people. The biology and epidemiology of RSV have been thoroughly documented, but researchers have yet to come up with a successful cure or a reliable vaccine. As a consequence, individuals with RSV infections have received a range of palliative medications; nevertheless, these therapies require significant medical resources, and for the vast majority part, their efficacy is still little understood. [3] Over the past few years, there has been some improvement in minimizing the effects of RSV. Outcomes research is starting to show which palliative treatments work best in both outpatient and hospital settings, and palivizumab (Synagis), a potent but expensive human recombinant monoclonal antibody preparation, has been produced to drastically reduce infection rates in patients. The creation of an effective vaccine is still the only way to prevent the yearly RSV pandemic due to RSV's extremely contagious nature, but that endeavor is still many years away. [4]

1.2 Epidemiology

All human populations are infected by the disease known as RSV. Most epidemics in the United States occur between the months of November and April, rising in December, January, and February17, with outbreaks spanning an average of 22 weeks. Pandemics wax and wane with seasonal variations. [5] In the pediatric population, RSV is typically the most common respiratory virus throughout the RSV season, while influenza an epidemic may coexist with RSV. At least 50% of infants in the United States are affected within

their first RSV season as a result of the disease's pervasiveness in the population, and almost all children have been exposed by the time they turn two. [6] Earlier to their second month of life, very few infants become sick, but after that, infection rates rise quickly, peaking in the third and fourth months of life. Reinfections are frequent since initial RSV infection does not significantly protect against future infection. With consecutive reinfections, the disease's intensity does, although, typically become less. [7] The occurrence of lower airway ailment reduced to 13% in the second year of life, 10.8% in the third year of life, and 7.7% in the fourth year of life in a study conducted in a number of families in Houston, Texas. However, 33% of RSV-infected infants had significant lower airway illness at that time. [8] Additional research, meanwhile, points to a higher prevalence of 20–50% lower airway illness in preschoolers with reinfections. 19 Re-infections are frequent, but they becoming less frequent as you get older. In a sequence of epidemiological investigations on respiratory diseases (the Tecumseh Investigations), RSV infection rates ranged from 20% of children aged 5 to 9 to 10% of children aged 15 to 19 and 5% of adults aged 20 to 50. [9]



Figure 1: Epidemiology of respiratory syncytial virus [10]

1.3 Risk Factors respiratory syncytial virus

Infants typically contract the most severe RSV infections. The most frequent causes of pneumonia and/or bronchiolitis are first infections. RSV is responsible for 50% of baby pneumonia cases and 80% of cases of childhood bronchiolitis. According on geography and socioeconomic circumstances, 0.1 to 1% of newborns in the United States with RSV infections need to be hospitalized. [11] Shay et al. recently examined hospitalized data for RSV infections throughout 1980 and 1996 and discovered that 81% of infants under one year and 57% of infants under six months were hospitalized for RSV infections. The study also showed a sharp rise in baby hospitalization rates during the course of the investigation. Bronchitis in babies boosted the hospitalization rate from 12.9 per 1,000 occurrences in 1980 to 31.2 per 1,000 cases in 1996. [12] It is noteworthy that pulse oximetry became

widely used during that time. Even when other indications indicate that hospitalization may not be required, the majority of doctors will admit any newborn with a respiratory infection and a pulse oximetry value of 92% to the hospital. Infants are more likely to contract RSV when certain conditions exist. [13] These include giving birth among April and September 30, using childcare services, living in close quarters, having siblings who are school age present, being premature, and being exposed to passive smoking inside the house. [14]



Figure 2: Risk Factors respiratory syncytial virus [15]

1.4 Pathophysiology of Respiratory Syncytial Virus

RSV is within the paramyxovirus category. Measles, mumps, and parainfluenza viruses (types 1, 2, and 3) are all closely related viruses. Only 10 genes make up the virus's single strand of ribonucleic acid (RNA), which makes up its whole genome. This RNA genome contains the genetic code for 11 different proteins. [16] Nine of these are surface glycoproteins and structural proteins that make up the viral coat and help the virus bind to the host cell. Once the virus has infected its host cell, the surviving 2 control the infection's reproduction process. The ciliated epithelial cells that lining the airways become infected by the virus. The viral particle must first adhere to a host cell, usually the nasal epithelium, in order to begin the viral replication process. [17] The viral RNA and viral enzymes subsequently enter the cell, where they control the synthesis of fresh viral RNA and proteins. The cell is eventually destroyed after the assembly of numerous new viruses. The signs of illness are finally brought on by the quick degeneration of ciliated epithelial cells lining the airways. It has been determined that the virus has two distinct strains, A and B. Both are contagious; one strain often predominates during a certain epidemic in a specific location, while both variants occasionally can be recovered from individuals in the same destination. [18] Despite its being noticed to alternating with Strain B in a slightly erratic way from year to year, Variant A is much more frequently found in the US and UK. Additional glycoprotein on the exterior of the viral coat, glycoprotein F, causes fusion of infected cells with nearby uninfected cells in additional to the virus fusing with particular cell membranes and injecting viral RNA into the cells. [19] This causes the membranes of infected cells to merge, enabling the viral RNA to be transmitted from cell to cell. The virus gets its name from the formations known as epithelial cell syncytia, which resemble enormous, multinucleate cells. The virus can also propagate by this method of cell-to-cell dissemination despite falling into touch with antibodies in nasal secretions. Additionally, a number of the recognized to be powerful bronchoconstrictors leukotrienes C4 and D4 as well as other pro-inflammatory mediator chemicals have been identified from the discharges of people with severe lower respiratory tract infections. [20] Small airways get clogged with secretions and cell debris as a consequence of increased secretory production, poor secretion clearance due to impaired mucociliary elevator action, and inadequate surfactant activity. Small airways may become even more constricted as a result of the

production of bronchoconstrictor chemicals, increasing airway resistance, air entrapment, and wheezing—symptoms that are typical of significant lower respiratory tract RSV infections. [21]



Figure 3: Pathophysiology of respiratory syncytial virus [22]

1.4.1 Immune Response to Infection

An immunological mechanism is developed by the body in response to an RSV infection. RSV-specific IgG, IgM, and IgA antibodies are subsequently produced and can be identified in both serum and airway secretions. Furthermore, the development and utility of these antibodies is a very intricate subject. The significance of their existence is supported by three lines of evidence. [23] First, they undoubtedly help to eradicate the specific illness that gave rise to them, but they do not always guard against other infections.

However, the existence of serum antibodies presumably explains the documented decline in the degree and frequency of reinfections. An immunological mechanism is developed by the body in response to an RSV infection. RSV-specific IgG, IgM, and IgA antibodies are subsequently produced and can be identified in both serum and airway discharges. [24] Furthermore, the development and utility of these antibodies is a very intricate subject. The significance of their existence is supported by three lines of evidence. First, they undoubtedly help to eradicate the specific illness that gave rise to them, but certainly do not always guard against other infections. [25] However, the existence of serum antibodies presumably explains the documented decline in the degree and frequency of reinfections. Studies have revealed that mice afflicted with murine RSV have T lymphocytes moving into their lungs. Last but not least, people with immune system abnormalities who lacked the cellular component of the During RSV infection, immunological response but having the humoral (antibody generating) portion of the immune system intact demonstrate significant morbidity and persistent virus dissemination, demonstrating that the cellular element of the innate immunity plays a crucial role in clearing the infection. [26]

1.4.2 Infection Transmission

RSV is spread by direct contact with contagious secretions on environmental surfaces or by being in close proximity to someone who is actively ill. Nasal discharges on tissue or cloth can spread disease for up to 30 minutes, but those on hard surfaces such countertops, stethoscopes, flatware, or crib rails can spread disease for at least 6 to 12 hours. Large-particle aerosols (such those produced by sneezes) traveling small distances and hand-to-eye or hand-to-nasal epithelium contact after coming into touch with infectious discharges are the two main ways that infections are transmitted into the body. [27] Including from one person to another's hands, infectious fluids can be transmitted. Aerosolized small particle distribution does not seem to be a frequent method of transmission. The incubating phase lasts for 2 to 8 days following the first contact, with 4-6 days being the most common duration. People who have the virus are still infectious as long as they are shedding it. Within a day or so of infection, the virus starts to shed, frequently before any noticeable symptoms appear. [28] The amount of virus that an individual sheds varies greatly and seems to generally correspond with their age, the intensity of their infection, and whether or not they have impaired immune systems. Adults often shed the virus for 3 to 7 days after

infection. In milder infections, babies can shed for up to 14 days, but babies older than 6 months who have severe infections can shed for up to 3 weeks. [29]

1.5 Diagnosis of respiratory syncytial virus

1.5.1 Signs and Symptoms

The sufferer will typically experience moderate to severe nasal congestion, limited fever (which usually goes away within a day or two), and a persistent cough within a few days of exposure and virus transfer to the nasal or ocular epithelium. [30] Particularly among those who have previously had an RSV infection, these indications may last as an upper respiratory infection for several weeks before going away without additional trouble. Furthermore, in babies, a lower respiratory tract infection is more likely to occur within 2-3 days of the onset of URI signs and symptoms (30–50%). Generally, a quarter to a half of newborns with the condition develop pharyngitis, coughing gets worse, and secretions are thicker and more profuse. [31] The infant may also display symptoms of respiratory distress, such as tachypnea, nasal flare-ups, denials, and a protracted expiratory phase. Coarse rales are audible across the chest, and one-half to three-quarters of newborns wheeze. Ultimately, nearly half of the infants who are afflicted vomit. A chest radiograph often reveals diaphragm flattening and hyperinflation. [32] Areas of interstitial infiltration also frequently manifest in significant lower respiratory tract infections, most typically in the right upper or middle lobes. Lethargy and poor eating may be the sole signs of a respiratory infection that very young newborns exhibit, as compared to those more normal symptoms. A chest radiograph often reveals diaphragm flattening and hyperinflation. Regions of interstitial infiltration also regularly manifest in significant lower respiratory tract infections, most typically in the right upper or middle lobes. [33]

Lethargy and poor eating may be the only indicators of a respiratory infection in very young newborns, as compared to the more normal ones. Additionally, extremely young infants frequently exhibit apnea and bradycardia, notably those who have a history of prematurity-related apnea or a congenital cardiac abnormality. One of the most potentially fatal features of RSV is this. [34] These newborns frequently have significant hypoxemia, severe dehydration, and they may have aspirated before showing up at a clinic or hospital emergency room.

1.5.2 Laboratory Diagnostic Testing

There are at least three different research lab methods for RSV identification. Material for all three approaches must be obtained from a sterile collection of nasal cleaning. Immunofluorescence and enzyme immunoassay are two methods used to check for RSV antigens in nasal washes. Functioning viruses that will multiply in cell culture are necessary for the third method, viral culture. [35] The most commonly employed method is the enzyme immunoassay, which has the advantages of relative affordability, quick turnaround (15–30 min), and usability. Industrially obtainable immunoassay assays provide a high level of specificity and sensitivity and are suitable for use by personnel without prior virology expertise. [36] When patients are admitted to the hospital with the aforementioned signs and symptoms, diagnostic tests can help to determine whether RSV is present. Although it is usually challenging to differentiate between RSV and bacterial pneumonia, a positive diagnosis of RSV will minimize the need for antibiotics and enable the implementation of effective measures for infection control as soon as feasible. This is crucial since one of the most prevalent ways that RSV is transmitted is through nosocomial infection. [37]

Chapter 2
Purpose of the study

2.1 Purpose of the study

One of the most severe pathogenic infections in children, respiratory syncytial virus (RSV) is known to cause significant morbidity. **Purpose of this review to know the following points.**

To know better diagnosis procedure of Respiratory syncytial virus

To find out clinically developed treatment for Respiratory syncytial virus

To know the etiology of this virus infection

To know the transmission (person to person) process of Respiratory syncytial virus

To find out prevention process for this viral infection

To know pathogenesis of Respiratory syncytial virus

To know the better diagnostic process for this illness

To know the approved treatment for this viral disease

Chapter 3
Methodology

3.1 Methodology

Methods for assembly and analyzing data, collected number of many related review paper from 2000 to 2022 review paper by using many search engines like PubMed, Research Gate, Google scholar and Medline etc. This chapter discusses the methods used in the investigation. I was searched by using some fundamental phrases including "Respiratory syncytial virus etiology," “Respiratory syncytial virus transmission," "Respiratory syncytial virus treatment," and "Respiratory syncytial virus preventive measures”. Finally, I was reviewed all collected paper & summarized data.

Chapter 4
Literature Review

4.1 Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection

The most common viral cause of death in children under the age of two is respiratory syncytial virus, which is also a growing cause of morbidity and mortality in older people and transplant patients. Upper and lower respiratory tract infections brought on by the respiratory syncytial virus can develop into significant bronchiolitis and pneumonia. Toddlers with a background of preterm birth along with or without chronic lung disease, kids with congenital heart disease, kids with cystic fibrosis or chronic lung problems, and immunocompromised or immunodeficient patients are elevated populations for severe respiratory syncytial virus infection. Nevertheless, the preponderance of newborns with severe respiratory syncytial virus illness are healthy and born at full term. A respiratory syncytial disease immunological pathologic pathway has long been suspected as to why children, the elderly, and those who are immunosuppressed are at significantly higher risk for severe illness. The creation of a secure and efficient vaccination against the respiratory syncytial virus has been unsuccessful. Despite being effective as a preventative measure, ant respiratory syncytial virus immunotherapy has no positive clinical effects when used pharmacologically. This shows that respiratory syncytial virus-induced pathology is most likely the result of the inflammatory response to infection rather than a direct viral cytopathic effect. Therefore, the most secure and effective method of treating acute respiratory syncytial virus infection may be a therapy that combines antiviral and anti-inflammatory medications. The existing state of knowledge that served as the foundation for the establishment of these kind of therapy is outlined in this review. [38]

4.2 Respiratory Syncytial Virus Infection in Adults

In some adult populations, respiratory syncytial virus (RSV) is now acknowledged as a serious issue. These people have included the elderly, those who have heart and lung conditions, and immunocompromised hosts. According to epidemiological data, the effects of RSV in older persons may be comparable to those of no pandemic influenza. RSV has also been linked to 2 to 5% of adult community-acquired pneumonia cases. In nursing facilities, attack rates range from 5 to 10% annually, with substantial pneumonia rates (10–20%) and fatality rates (2–5%). Nasal congestion, coughing, wheezing, and low-grade fever are some of the clinical manifestations that might make it challenging to differentiate

them from influenza. Before to marrow engraftment, pneumonia and death probability are highest in bone marrow transplant patients. Although early bronchoscopy is helpful in immunocompromised patients, it is challenging to diagnose RSV infection in adults since viral culture and antigen detection are insensitive, perhaps because of low viral titers in nasal secretions. While early medication with ribavirin and intravenous gamma globulin is linked to improved lifespan in immunocompromised individuals, management of RSV in the elderly is primarily supportive. Since a viable RSV vaccine has not yet been created, standard infection control procedures including hand washing and the wearing of gowns and gloves are the only means of preventing RSV infection. [39]

4.3 New drugs and treatment for respiratory syncytial virus

Throughout many regions of the world, the respiratory syncytial virus (RSV) claims more lives than AIDS and affects infants and the aged. Ribavarin, a moderately indiscriminate antiviral, is used to manage it, and there are just two antibody medicines that are licensed for its prophylaxis. Several pharmaceutical and biotech businesses started RSV research initiatives in the middle of the 1990s. At one point, there were at least 25 active R&D activities that were jointly funded by academic and industrial institutions. These programs encompassed the entire range of antibodies, vaccines, synthetic small molecule antiviral, and antisense technologies. Consequently, a substantial reduction in such programs followed the 1998 launch of the monoclonal antibody palivizumab (Synagis®). Whereas the ongoing medical need, significant market size, and sales estimates clearly show that a safe and efficient RSV medicine or vaccine is likely to acquire blockbuster status, many businesses recently terminated RSV projects as they prioritized their R&D catalogs. RSV now receives a negligible portion of the R&D expenditure as contrasted to AIDS, for instance. This article examines the anti-RSV regimen's current situation, discusses drugs on the market and those being developed, makes an effort to connect basic research to industrial drug development, examines animal models of RSV, examines clinical trials, examines current clinical governance, and examines both the existence and the future market estimations. It is envisaged that the unmet medical needs of RSV sufferers will inspire the pharmaceutical and biotechnology industries to remain working on new secure. [40]

Chapter 5
Result & Discussion

5.1 Therapeutics

Since the virus's discovery, researchers have been working to create a viable medication for RSV infections, but so far only palliative treatments have been found to be successful. Numerous different therapy modalities have been developed and used, but most of them have failed to show promise in thorough clinical trials. [41]

5.1.1 Oxygen

The pulse oximetry values of people displaying the typical symptoms of a lower respiratory tract infection should be taken. It is necessary to give extra oxygen to keep the saturation level at 92%. [42]

5.1.2 Agonists

As RSV infections frequently induce wheezing, 2 agonists have been used to treat patients for more than 35 years. Therefore, the efficacy of 2 agonists is still questionable after several clinical investigations. The effects of bronchodilators (albuterol, metaproterenol, or ipratropium) were examined in a total of 24 published investigations. The features of these investigations. [43] There aren't many reliable assumptions that can be drawn from these investigations when taken as a whole. The experiments were meticulously planned; 63% of them were double-blind and placebo-controlled, and all included controls. However, as there is no uniformity between studies in factors like patient criteria for inclusion, medicine dose and regimen, or assessment of illness severity, meaningful correlations are very challenging. [44] To determine if a favorable bronchodilator treatment when in an RSV infection genuinely treats the RSV infection instead of underlying asthma, for instance, there was no attempt to find patients with which was before atopy for selection from the investigations. The research' objective criterion also vary considerably. In almost two thirds of the trials, the bronchodilator impact was assessed using changes in pulmonary function measures including peak exhalation flow at functional residual capacity, airway rigidity, system compliance, or effort of breathing. [45] Many of these measurements are responsive to extremely slight changes in pulmonary function, although most bedside situations make it difficult to use them. The remaining investigations utilized length of stay, variations in arterial oxygen saturation, or respiratory distress score methods to assess

results; however, these may not be as comprehensive as pulmonary function measures. [46] Regrettably, no study made an effort to validate real-world clinical indicators by connecting them to actual alterations in pulmonary function. In 50% of the investigations, the use of a bronchodilator resulted in some sort of favorable reaction. This is rather deceiving, though, as only roughly 30–50% of the subjects in each of these experiments responded favorably. [47] The remaining either had no reaction or, in some circumstances, deteriorated. The pathophysiology of RSV serves as the foundation for both the usage of 2 activator bronchodilators and a knowledge of their unique effects. The purpose of bronchodilators is to treat wheezing, air entrapment, and enhanced airway resistance that are only brought on by restriction of the bronchiolar smooth muscle. [48] Reduced discharge, sloughing of injured airway epithelium into the airway lumen, interfacial and mucosal edema, and maybe humorally or neurogenically related bronchoconstriction are at least four different explanations of reduced airway dimension and the associated wheeze in RSV. Furthermore, the proportional importance of each of these, notably bronchoconstriction, is likely to differ greatly between people. [49] Only bronchoconstriction is addressed by 2 agonists. Last but not least, inadequate aerosol absorption into an infant's peripheral airways may potentially reduce bronchodilator efficiency. Utilizing radiolabeled albuterol, Amirav et al.121 shown that just 0.6% of the albuterol exiting the nebulizer really entered the newborns' tiny airways. [50] They contend that this is woefully insufficient and that the introduction of ultra-fine particles could enhance the administration of medicament to newborn lung's peripheral airways. This is consistent with the finding of several researchers that bronchodilator medication appears to work best in the early stages of the illness, most likely when tiny airways are less congested with fluids and cellular debris. [51]

5.1.3 Racemic Epinephrine

RSV infection manifestations have also been treated with epinephrine, which can be administered orally or intravenously (racemic epinephrine). A review of ten studies on the effectiveness of epinephrine was conducted. enumerates the features of various investigations. In all but two of the trials reviewed, racemic epinephrine injection increased oxygenation, transcutaneous determined PO2, respiratory distress score, and pulmonary function measurements. [52] When contrasted to infants who received only albuterol

treatment in a hospital emergency department study, it also reduced the hospitalization rate by more than 50%. One of the two studies that failed to find an enchantment assessed infants who had healed from RSV infection but continued to wheeze frequently. Positive reactions just seem to happen in almost all patients when they did. According to Lowell et al., 70% of the RSV patients had a positive response. [53] All five research that examined the effects of epinephrine on bronchiolitis patients found substantial clinical benefit, a reduction in respiratory rate, and a reduction in wheezing, according to a meta-analysis of five trials. In two of the evaluated trials, there were fewer hospital admissions and faster discharges as well. Once more, the pathophysiology of RSV infection could best be described in terms of the differences between patient responses to epinephrine and albuterol. Since it has adrenergic α1 action, epinephrine could be more successful at reopening tiny airways than an adrenergic bronchodilator at reducing interfacial and mucosal edema. [54]

5.1.4 Aerosolized Recombinant Human DNase

The impact of aerosolized recombinant human DNase (Pulmozyme) in newborns with RSV illnesses has been studied in one randomization, placebo-controlled research and one case series of five infants. In the trial, chest radiograph ratings for newborns getting DNase significantly increased whereas those for infants getting placebo decreased throughout the same time frame. [55] Other metrics, like an increase in respiratory rate, wheezing, and retractions while in the hospital, did not differ substantially between the DNase group and the placebo group. DNase was given to 5 RSV-infected children in the case series, 2 of them had "severe unilateral atelectasis" and were about to go into respiratory distress, while the other three were already receiving mechanical ventilation. The 2 infants who did not require intubation and the 3 patients receiving mechanical ventilation swiftly improved clinically and radiologically. [56]

5.1.5 Inhaled and Systemic Corticosteroids

Both the acute phase of bronchiolitis and the period of persistent wheeze that follows RSV infection in many newborns are frequently treated with corticosteroids. Evaluation of 17 research' findings that looked at this treatment's efficacy. Long follow-up periods were used in several research, which once again produced conflicting findings. Only one of the

five studies that had follow-up in the 1–5 years following infection had findings that indicated a sizable advantage from steroid therapy. [57] It does not appear to be necessary to perform pulmonary function tests to demonstrate the benefits of steroid usage. The output variable in each of the three studies that shown an advantage from steroids was either respiratory scoring, pulse oximetry, or incidence of wheeze. The prevalence of antecedent atopy or asthma as well as steroid use in the past are two additional complicating factors that make it challenging to research the efficacy of steroids for RSV. The majority of the studies examined here either do not specifically rule out patients who have a background of wheezing or steroid usage, or else they do not highlight it when explaining how they choose their patients. [58] Only 2 of the 6 studies that Garrison et al. examined precisely eliminated individuals with past steroid usage; conversely, 4 of the 6 studies specifically exempted patients with a background of wheezing. The pathophysiology of RSV indicates that corticosteroids' anti-inflammatory effects might be an efficient form of treatment for infections. Yet, the effectiveness of steroid treatment for RSV remains unknown despite all the clinical research conducted too far. [59] There is an urgent need for well-planned, multicenter trials with stringent patient eligibility criteria, clearly delineated medication administration schedules, and extensive follow-up. Yet, at this time, only two suggestions seem sensible. First, for hospitalized patients with moderate severity infections, inhaled corticosteroids seem to be just as beneficial as systemic corticosteroids due to their lower risk of side effects. Second, corticosteroids seem to be very useful in individuals with severe infections who need mechanical ventilation. Moreover, Garrison et al. pointed out that children with the most serious infections seem to recover from steroids the most. [60]

5.1.6 Ribavirin

The only antiviral treatment permitted for RSV infections is ribavirin (Virazole). It reduces the IgE action and slows viral multiplication by preventing the creation of viral structural proteins. The National Library of Medicine's PubMed database was used to review the findings of more than 100 research looking at the effectiveness of ribavirin. There have been many double-blind, placebo-controlled articles conducted; even so, the majority of these have had disappointingly variable and contradictory outcomes due to their small sample sizes (20–50 newborns). [61] Also, the usage of ribavirin has been debated for both

economic and safety reasons due to how labor-intensive and dangerous it is to administer. Early double-blind, placebo-controlled studies showed that children who had formerly been healthy, newborns who had underlying cardiac disease, and infants who needed mechanical ventilation for serious infections all experienced faster clinical benefit when given ribavirin aerosol. In the pediatric literature, the use of ribavirin was editorial content welcomed with considerable enthusiasm. [62] Conversely, more current research has not supported prior promising findings. For instance, no statistically significant beneficial benefit of ribavirin on infants who were continuously ventilated was discovered in 2 relatively randomized prospective, placebo-controlled investigations. Early double-blind, placebo-controlled investigations showed that children who had formerly been healthy, newborns who had preexisting cardiac disease, and infants who needed mechanical ventilation for serious infections all experienced more fast clinical benefit when given ribavirin aerosol. [63] In the pediatric research, the use of ribavirin was editorial content welcomed with considerable enthusiasm. Conversely, more current research has not supported prior promising findings. For instance, no statistically significant beneficial benefit of ribavirin on infants who were continuously ventilated was discovered in 2 relatively randomized prospective, placebo-controlled investigations. [64]

5.1.7 Vitamin A

Children with RSV infections had considerably lower serum vitamin A levels, which could have contributed to the infection's extremely engage in critical. These findings suggested that supplementing with vitamin A might be beneficial. In contrast, oral vitamin A therapy in children with acute RSV bronchiolitis did not reduce respiratory morbidity in a later research. [65]

5.1.8 Antimicrobial therapy

In patients with RSV bronchiolitis, the likelihood of a subsequent bacterial infection is quite low. Thus, it is not necessary to regularly use antibiotics to manage RSV bronchiolitis. The diagnostic and therapeutic assessment of the patient, raised WBC, and raised CRP all have a role in whether or not antibiotics should be started. Bacteremia has been linked to WBCs higher than 15 '/l. Though WBCs can rise up to 20'109 /l in an RSV infection, serum CRP levels are typically low. [66] We recommend only administering

antibiotics to kids who experience an unexplained clinical worsening and a rise in inflammatory markers like CRP.

5.1.9 Interferon

In responding to viral infections, leucocytes generate interferon (IFN), which can make host cells less susceptible to viral reproduction. When contrasted to responses induced by other respiratory viruses, including influenza, researchers discovered that the IFN responsiveness to RSV infection in children was relatively low. [67] A double-blind, placebo-controlled trial was carried out by Higgins et al. to examine the clinical and preventative effectiveness of IFN-2a. IFN-2a had a preventive effect, however neither the severity of the signs and symptoms nor the length of the illness were affected. IFN-2a consequently serves little purpose in the management of RSV infections. [68]

5.2 Vaccination

In the 1960s, a formalin-inactivated aluminum-precipitated RSV vaccine was created and put to the test in newborns and kids. However, this vaccine not only did not offer protection versus containing natural RSV contamination, but it also triggered an immune-mediated activation upon reexposure to the virus, increasing death and hospitalization probabilities for lower respiratory tract pathology. [69] In animal models, the pathophysiology of this process was studied. High amounts of antibodies against by the F and G proteins were seen in the cotton rat because formalin did not completely destroy all of the epitopes on the F and G glycoproteins. This triggered an abnormal immunological response that worsened the pulmonary histopathology. Despite the fact that the presence of maternal antibodies from placental transfer and breast milk appears to provide considerable immunity in the first one to two months of life, it also has the potential to impair the infant's own immune response to a vaccine. [70] Moreover, an RSV vaccine may hinder the effectiveness of other vaccinations delivered at the same moment. The creation of a vaccination is being sought using many methods. While a second upper respiratory infection is typically not prevented by a first RSV infection, in an immunocompetent person it typically does preclude a more serious lower respiratory illness from returning. [71] It might not be possible to completely prevent infection if the aim of a vaccine is to mimic the immunity

brought on by a natural infection. A live, attenuated vaccination has long been a goal of researchers. Although these potential pathogens have been studied in animals, tests on adult people have shown them to be either too virulent, too attenuated, or too unstable. [72] However, because to the recently discovered power to duplicate and alter the viral genome down to the level of the individual nucleotide, work is currently underway on a genetically designed attenuated viral strain. Another strategy under consideration is immunizing expectant mothers during their final trimester of pregnancy in order to increase the amount of antibodies they carry on to the child right before birth. [73] Moreover, efforts are being made to develop a vaccine that would boost the production of antibodies against glycoproteins F and G in immunocompromised people who have already experienced at least one RSV infection. Unsuccessful vaccine development will take a long time. Before to being tested on the most vulnerable human populations, such as healthy adults, children, and newborns, it must first be created and evaluated in animals (a challenging task because there is no reliable animal model for RSV). Ultimately, the creation of many vaccinations with diverse populations in mind may be necessary for an effective RSV strategy. [74]

5.2.1 IgG monoclonal antibodies

An anti-RSV humanized IgG monoclonal antibody known as MEDI493 was created by Johnson and colleagues. First, different doses of MEDI-493 were intravenously given to infants who had been born prematurely (at O35 weeks gestation) and had BPD who were under 24 months old, with 0.9% saline serving as a placebo. Few negative incidents were noticed. [75] In a subsequent research, MEDI-493 given intramuscularly produced comparable outcomes. Using animal models as a guide, monthly intramuscular injections of 15 mg/kg produced mean serum concentrations over 40 lg/ ml, which are linked to a 99% decrease in lung RSV titre. Over RSVIG, palivizumab provides a number of benefits. It is simple to administer and does not conflict with routine vaccines. [76] Current suggestions from the American Academy of Pediatrics to use palivizumab for specific conditions have come under fire [90], as one main drawback is the expensive price. The average cost per patient every season is $4500 per year. Regardless of the underlying illness state, the Number-Needed-to-Treat with palivizumab was determined as 17 to avoid one RSV hospitalization. [77]

Chapter 6
Conclusion

6.1 Conclusion

Children with RSV infections cannot presently get an effective treatment. Hence, the majority of RSV infection treatment continues to be symptomatic. Corticosteroids, vitamin A, INF, and antibiotics are not advised because to their ineffectiveness. Despite the lack of scientific proof data supporting their usual usage, bronchodilators may be used in certain patients. Ribavirin is no longer recommended as a standard treatment for RSV infections in elevated children. Only patients with T-cell immunodeficiency may be considered for treatment with this medication. The creation of a vaccine is progressing reasonably on a lot of fronts despite the challenges. Nonetheless, scientific proof clinical practice recommendations should be followed in the interim to prevent wasting the limited medical available resources until this vaccine is available. Clinical practice recommendations are undeniably very efficient, and once implemented, they can be maintained and the gains made can continue.

Chapter 7
Reference

Reference

1. Dennehy PH. Epidemiology and risk factors. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:37–71.

2. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 2001:183(1):16–22.

3. MacDonald NE, Hall CB, Suffin SC, Alexson D, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307(7):397–400.

4. McBride JT. Pulmonary function changes in children after respiratory syncytial virus infection in infancy. J Pediatr 1999;135(2 Pt 2):28–32.

5. Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med 1997;102(3A):61–70; discussion 75–76.

6. Hemming VG. Respiratory syncytial virus: a brief history. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:7–23.

7. Adams J. Primary virus pneumonitis with cytoplasmic inclusion bodies: a study of an epidemic involving thirty-two infants with nine deaths. JAMA 1941;116:925–933.

8. Hilleman MR. Respiratory syncytial virus. Am Rev Respir Dis 1963;88:181–197.

9. Jeffcoate TN. Vaccine against respiratory syncytial virus. Lancet 1969;2(7615):311.

10. Rodriguez WJ, Kim HW, Brandt CD, Fink RJ, Getson PR, Arrobio J, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J 1987;6(2): 159–163.

11. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, etal. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection: a randomized double-blind study. N Engl J Med 1983;308(24):1443–1447.

12. Smith DW, Frankel LR, Mathers LH, Tang ATS, Arriagno RL, Porber CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus. N Engl J Med 1991;325(1):24–29.

13. American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996;97(1):137–140.

14. Bowden RA. Respiratory virus infection after marrow transplant: The Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102(3A):27–30; discussion 42–43.

15. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997;99(1):93–99.

16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact RSV Study Group. Pediatrics 1998;102(3):531–537.

17. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979; 300(10):530–534.

18. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288(10):498–505.

19. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140(6):543–546.

20. Monto AS, Lim SK. The Tecumseh study of respiratory illness. III. Incidence and periodicity of respiratory syncytial virus and Mycoplasma pneumoniae infections. Am J Epidemiol 1971;94(3):290–301.

21. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161(3):402–406.

22. Welliver R, Cherry JD. Bronchiolitis and infectious asthma. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases, 2nd ed. Philadelphia: WB Saunders; 1987:278–288.

23. Murphy TF, Henderson FW, Clyde WA Jr, Collier AM, Denny FW. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 1981;113(1):12–21.

24. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 1999:282(15):1440–1446.

25. Carlsen KH, Larsen S, Bjerve O, Leegaard J. Acute bronchiolitis: predisposing factors and characterizations of infants at risk. Pediatric Pulmonol 1987;3(3):153–160.

26. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98(5):708–715.

27. McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986;140(8):806–812.

28. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19(7):592–597.

29. Simoes EAF, King SJ, Lehr MV, Groothuis JR. Preterm twins and triplets: a high-risk group for severe respiratory syncytial virus infection. Am J Dis Child 1993;147(3):303–306.

30. Simoes EAF, Groothuis JR. Respiratory syncytial virus prophylaxis—the story so far. Respir Med 2002;96 Suppl B:S15–S24.

31. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88(3):527–532.

32. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113(5):826–830.

33. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998;26(6):371–379.

34. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103(3): 619–626.

35. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV data base. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999;18(10):866–869.

36. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307(7):397–400.

37. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121(3):348– 354.

38. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20(10):1406–1413.

39. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986; 315(2):77–81.

40. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98(4): 289–300.

41. Glezen WP. Pathogenesis of bronchiolitis—epidemiologic considerations. Pediatr Res 1977;11(3 Pt 2):239–243.

42. Denny FW, Collier AM, Henderson FW, Clyde WA Jr. The epidemiology of bronchiolitis. Pediatr Res 1977;11(3 Pt 2):234–236.

43. Brandt CD, Kim HW, Arrobio JO, Jeffries BC, Wood SC, Chanock RM, Parrott RH. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 1973;98(5):355–364.

44. Vardas E, Blaauw D, McAnerney J. The epidemiology of respiratory syncytial virus (RSV) infections in South African children. S Afr Med J 1999;89(10):1079–1084.

45. Harlap S, Davies AM. Infant admissions to hospital and maternal smoking. Lancet 1974;1(7857):529–532.

46. Hall CB. The nosocomial spread of respiratory syncytial virus infections. Annu Rev Med 1983;34:311–319.

47. Langley JM, LeBlanc JC, Wang EE, Law BJ, MacDonald NE, Mitchell I, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada study. Pediatrics 1997;100(6): 943–946.

48. Hall CB. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended. Clin Infect Dis 2000;31(2):590–596.

49. Hall CB, Geiman J, Douglas RG Jr, Meagher MP. Control of nosocomial respiratory syncytial viral infections. Pediatrics 1978;62(5):

728–732.

50. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163(4):693–698.

51. Hall CB. Respiratory syncytial virus and parainfluenza virus. New Engl J Med 2001;344(25):1917–1928.

52. Cane PA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2001;11(2):103–116.

53. Alberts B, Bray D, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Essential cell biology: an introduction to the molecular biology of the cell. New York: Garland Publishing; 1998:297–300.

54. Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, Anderson LJ. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990;162(6):1283–1290.

55. Freymuth F, Petitjean J, Pothier P, Brouard J, Norrby E. Prevalence of respiratory syncytial virus subgroups A and B in France from 1982 to 1990. J Clin Microbiol 1991:29(3):653–655.

56. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis 1997;175(4):814–820.

57. Wilson SD, Roberts K, Hammond K, Ayres JG, Cane PA. Estimation of incidence of respiratory syncytial virus infection in school children using salivary antibodies. J Med Virol 2000;61(1):81–84.

58. Chartrand SA. Current prevention strategies. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000: 153–175.

59. van Schaik SM, Welliver RC, Kimpen JLL. Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol 2000;30(2):131–138.

60. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 1996; 75(2):133–136.

61. van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC II, Welliver RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999;103(4):630–636.

62. Welliver RC. Immune response. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000: 94–121.

63. Kimpen JLL, Rich GA, Hohar CK, Ogra PL. Mucosal T cell distribution during infection with respiratory syncytial virus. J Med Virol 1992;36(3):172–179.

64. Hall CB, Douglas RG Jr, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980;141(1):98– 102.

65. Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. J Pediatr 1981;99(1):100–103.

66. Hall CB. Pathology and pathogenicity. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management

67. Karron RA, et al (1999) Evaluation of live recombinant RSV A2 vaccines in children over 6 months of age. In: RSV after 43 years, Stuart, Florida

68. Karron RA, Wright PF, Crowe Jr JE, Clements ML, Thompson J, Makhene M, et al (1997) Evaluation of two live, cold -passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and human adults, infants and children. J Infect Dis 176: 1428±1436

69. Kellner JD, Ohlsson A, Gadomski AM, Wang EEL (1996) Efficacy of bronchodilator therapy in bronchiolitis. a meta-analysis. Arch Pediatric Adolesc Med 150: 1166±1172

70. Kellner JD, Ohlsson A, Gadomski AM, Wang EEL (1999) Bronchodilators for bronchiolitis (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: Update Software

71. Kim HW, Arrobio JO, Brandt CD, Jeries BC, Pyles G, Reid JL, et al (1973) Epidemiology of respiratory syncytial virus infection in Washington DC: importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 98: 216±225

72. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactived vaccine. Am J Epidemiol 89: 422±434

73. Kimpen JLL, Garofalo R, Welliver RC, Ogra PL (1992) Activation of human eosinophils in vitro by respiratory syncytial virus. Pediatr Res 32: 160±164

74. Kimpen JLL, Schaad UB (1997) Treatment of respiratory syncytial virus bronchiolitis: 1995 poll members of the European Society for Paediatric Infectious Diseases. Pediatr Infect Dis J 16: 479±481

75. Klassen TP, Rowe PC, Sutclie T, Ropp LJ, McDowell IW, Li MM (1991) Randomized trial of salbutamol in acutebronchiolitis. J Pediatr 118: 807±811

76. Klassen TP, Sutclie T, Watters LK, Wells GA, Allen UD, LiMM (1997) Dexamethasone in salbutamol-treated in patients with acute bronchiolitis: a randomized, controlled trial. J Pediatr 130: 191±196

77. Kneyber MCJ, Brandenburg AH, Groot R de, Rothbarth PhH, Ott A, Moll HA (1996) Relationship between clinical severity of RSV infection and subtype. Arch Dis Child 75:137±140